Birmingham, West Midlands — (TechSonian) — July 08, 2014 — PDL BioPharm, (NASDAQ:PDLI), manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies.
PDL BioPharma Inc (NASDAQ:PDLI) decreased -0.74% at the price of $9.45 recently on a traded volume of 1.31 million shares, in comparison to 1.95 million shares of average trading volume. The company has a total market capitalization of $1.52 billion.
Has PDLI Found The Bottom and Ready To Move Up? Find Out Here
EXCO Resources, (NYSE:XCO), an independent oil and natural gas company, is involved in the acquisition, exploration, exploitation, development, and production of onshore oil and natural gas properties with a focus on shale resource plays in the United States. As of December 31, 2013, the company had almost 70,000 net acres in East Texas/North Louisiana region for the Haynesville and Bossier shale formations; 47,800 net acres in South Texas region for the Eagle Ford shale formation; and 145,000 net acres in Appalachia region prospective for the Marcellus shale formation.
EXCO Resources Inc (NYSE:XCO) soared 0.37% at the trading price of $5.45 on a traded volume of 1.69 million shares till now, whereas its average trading volume is 3.76 million shares. The Intra-day range for the stock is $5.38 and $5.52.The company has a total market capitalization of $1.49 billion.
For How Long XCO Gloss will Attract Investors? Find out via this report
IAMGOLD, (NYSE:IAG), explores, develops, and operates gold mining properties. The company also explores for silver, niobium, and copper deposits.
IAMGOLD Corp (USA) (NYSE:IAG) dropped down -2.03% at the $3.87 recently. The 52-week range for the stock is $3.00 and $7.08. Its introductory price for the day was $4.01, with the overall traded volume of 5.77 million shares.
Why Should Investors Buy IAG After the Recent Fall? Just Go Here and Find Out
Keryx Biopharmaceuticals, (NASDAQ:KERX), reported that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,754,257 and No. 8,754,258. The patents, which expire in 2024, claim pharmaceutical compositions comprising a form of ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm2/min, and orally administrable forms of ferric citrate prepared from a form of ferric citrate having an intrinsic dissolution rate of at least 1.88/mg/cm2/min, respectively.
Keryx Biopharmaceuticals (NASDAQ:KERX) after opening its shares at the price of $15.54, dropped -5.00%, its recent trading price was $14.83 for the day. The stock moved on a traded volume of 1.27 million shares, in comparison to 1.51 million shares of average trading volume.
The 52-week range for the stock is $7.90 and $17.46.
Will KERX Get Buyers Even After The Recent Rally? Find Out Here